 |
Hot Pursuit
17-Mar-25
|
|
|
|
|
|
|
|
|
|
|
|
Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations
|
|
Alkem Laboratories added 1.93% to Rs 4,795 after the company announced that the United States Food and Drug Administration (USFDA) conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra.
|
|
|
|
|
|
The inspection, conducted from March 10 to March 13, 2025, concluded that no Form 483 had been issued.
Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.
The company’s consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25.
|
|
|
|
Previous News |
Alkem Laboratories consolidated net profit rises 5.19% in the December 2024 quarter
(
Results
-
Announcements
07-Feb-25
17:22
)
|
|
|
Sensex, Nifty end at record closing highs, Nifty Bank hits all-time high
(
Market Commentary
-
Quick Review
25-Jun-24
15:43
)
|
|
|
Alkem Laboratories
(
Results
-
Analysis
09-Aug-24
19:25
)
|
|
|
Alkem Laboratories Ltd leads losers in 'A' group
(
Hot Pursuit
-
26-Feb-24
15:00
)
|
|
|
Alkem incorporates WoS named Alixer Nexgen Therapeutics
(
Corporate News
-
15-Jul-24
15:39
)
|
|
|
Alkem Laboratories consolidated net profit rises 124.64% in the June 2023 quarter
(
Results
-
Announcements
12-Aug-23
13:47
)
|
|
|
Board of Alkem Laboratories approves transfer of its trade generics biz to Alkem Wellness
(
Corporate News
-
10-Dec-24
15:08
)
|
|
|
Alkem Lab Q1 PAT more than doubles to Rs 287 cr
(
Hot Pursuit
-
10-Aug-23
15:30
)
|
|
|
Zydus Lifesciences Ltd Slides 1.88%
(
Hot Pursuit
-
18-Jun-24
09:30
)
|
|
|
Alkem Laboratories to announce Quarterly Result
(
Corporate News
-
10-May-23
12:34
)
|
|
|
Alkem Laboratories to declare Quarterly Result
(
Corporate News
-
25-Jul-24
16:59
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|